Corrections

Am Fam Physician. 2008 Jun 1;77(11):1505.

The Tips from Other Journals article “New Guideline for Travel Medicine,” (September 15, 2007, page 878) contained an error in Table 2 on page 883. The dosage for atovaquone/proguanil (Malarone) was incorrectly listed as “250/100 mg every day, beginning one to two days pretravel and continuing until 28 days posttravel.” The correct dosage is “250/100 mg every day, beginning one to two days pretravel and continuing until seven days posttravel.” The online version of this article has been corrected, and the corrected table is reprinted below.

Table 2

Antimalarial Medication Recommendations by Destination

Destination Medication

Argentina and Paraguay, Central America, Haiti and Dominican Republic, Middle East

Chloroquine (Aralen): 500 mg every week, beginning one week pretravel and continuing until four weeks posttravel

Asia, South America (except Argentina and Paraguay), sub-Saharan Africa

Atovaquone/proguanil (Malarone): 250/100 mg every day, beginning one to two days pretravel and continuing until seven days posttravel

or

Mefloquine (Lariam): 250 mg every week, beginning one week pretravel and continuing until four weeks posttravel*


note: Risk (including drug-resistant strains) may be restricted to regions of some countries; targeted recommendations are available at http://www.cdc.gov/travel.

*— Mefloquine is not recommended for travelers to western Cambodia and forested areas of Thailand-Cambodia and Thailand-Burma borders because of multidrug-resistant Plasmodium falciparum.

Table 2   Antimalarial Medication Recommendations by Destination

View Table

Table 2

Antimalarial Medication Recommendations by Destination

Destination Medication

Argentina and Paraguay, Central America, Haiti and Dominican Republic, Middle East

Chloroquine (Aralen): 500 mg every week, beginning one week pretravel and continuing until four weeks posttravel

Asia, South America (except Argentina and Paraguay), sub-Saharan Africa

Atovaquone/proguanil (Malarone): 250/100 mg every day, beginning one to two days pretravel and continuing until seven days posttravel

or

Mefloquine (Lariam): 250 mg every week, beginning one week pretravel and continuing until four weeks posttravel*


note: Risk (including drug-resistant strains) may be restricted to regions of some countries; targeted recommendations are available at http://www.cdc.gov/travel.

*— Mefloquine is not recommended for travelers to western Cambodia and forested areas of Thailand-Cambodia and Thailand-Burma borders because of multidrug-resistant Plasmodium falciparum.


Copyright © 2008 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

Navigate this Article